Colinz Laboratories Past Earnings Performance
Past criteria checks 3/6
Colinz Laboratories has been growing earnings at an average annual rate of 28.7%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been declining at an average rate of 1.6% per year. Colinz Laboratories's return on equity is 5.6%, and it has net margins of 6.7%.
Key information
28.7%
Earnings growth rate
39.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -1.6% |
| Return on equity | 5.6% |
| Net Margin | 6.7% |
| Next Earnings Update | 29 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Colinz Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 71 | 5 | 32 | 0 |
| 30 Sep 23 | 71 | 5 | 32 | 0 |
| 30 Jun 23 | 72 | 5 | 32 | 0 |
| 31 Mar 23 | 72 | 5 | 32 | 0 |
| 31 Dec 22 | 70 | 4 | 32 | 0 |
| 30 Sep 22 | 69 | 4 | 31 | 0 |
| 30 Jun 22 | 70 | 4 | 30 | 0 |
| 31 Mar 22 | 70 | 3 | 30 | 0 |
| 31 Dec 21 | 70 | 3 | 31 | 0 |
| 30 Sep 21 | 69 | 3 | 32 | 0 |
| 30 Jun 21 | 66 | 2 | 28 | 0 |
| 31 Mar 21 | 62 | 2 | 27 | 0 |
| 31 Dec 20 | 62 | 1 | 27 | 0 |
| 30 Sep 20 | 66 | 2 | 28 | 0 |
| 30 Jun 20 | 70 | 1 | 31 | 0 |
| 31 Mar 20 | 76 | 1 | 36 | 0 |
| 31 Dec 19 | 76 | 2 | 33 | 0 |
| 30 Sep 19 | 76 | 1 | 34 | 0 |
| 30 Jun 19 | 76 | 1 | 33 | 0 |
| 31 Mar 19 | 77 | 1 | 34 | 0 |
| 31 Dec 18 | 78 | 2 | 37 | 0 |
| 30 Sep 18 | 78 | 3 | 35 | 0 |
| 30 Jun 18 | 82 | 3 | 34 | 0 |
| 31 Mar 18 | 79 | 2 | 34 | 0 |
| 31 Dec 17 | 78 | 1 | 35 | 0 |
| 30 Sep 17 | 75 | 1 | 30 | 0 |
| 30 Jun 17 | 72 | 1 | 30 | 0 |
| 31 Mar 17 | 76 | 1 | 32 | 0 |
| 31 Dec 16 | 77 | 1 | 29 | 0 |
| 30 Sep 16 | 79 | 1 | 29 | 0 |
| 30 Jun 16 | 79 | 1 | 29 | 0 |
| 31 Mar 16 | 81 | 1 | 29 | 0 |
| 31 Dec 15 | 80 | 1 | 28 | 0 |
| 30 Sep 15 | 79 | 1 | 28 | 0 |
| 30 Jun 15 | 81 | 1 | 28 | 0 |
| 31 Mar 15 | 79 | 1 | 28 | 0 |
| 31 Dec 14 | 80 | 1 | 37 | 0 |
| 30 Sep 14 | 80 | 1 | 35 | 0 |
| 30 Jun 14 | 76 | 1 | 26 | 0 |
| 31 Mar 14 | 74 | 1 | 34 | 0 |
| 31 Dec 13 | 72 | 0 | 34 | 0 |
| 30 Sep 13 | 70 | 0 | 25 | 0 |
| 30 Jun 13 | 69 | 1 | 25 | 0 |
Quality Earnings: 531210 has high quality earnings.
Growing Profit Margin: 531210's current net profit margins (6.7%) are higher than last year (5.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 531210's earnings have grown significantly by 28.7% per year over the past 5 years.
Accelerating Growth: 531210's earnings growth over the past year (19.3%) is below its 5-year average (28.7% per year).
Earnings vs Industry: 531210 earnings growth over the past year (19.3%) did not outperform the Pharmaceuticals industry 23.3%.
Return on Equity
High ROE: 531210's Return on Equity (5.6%) is considered low.